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Abstract
The Precision Medicine Initiative aims to advance Medicine from “one-size-fits-all”
treatments to more individualized approaches. Clinical trials evaluate treatments by
analyzing average outcomes, and thus risk overlooking potential differences in treatment
effect among different subsets of the study population. The use of multivariate models
has been proposed as a way to identify heterogeneity of treatment effect and to determine
patients’ individualized treatment risks and benefits.

We analyzed the Randomized Evaluation of Long-Term Anticoagulation Therapy
(RELY) trial of dabigatran versus warfarin in patients with atrial fibrillation, to determine
if the application of multivariate predictive models could demonstrate heterogeneity of
treatment effect among the study population. We developed two models to predict
patients’ risk of stroke or systemic embolism and risk of major bleeding if treated with
dabigatran or warfarin. We then applied these models to the individual patients in the RELY trial, and determined patients difference in risk if treated with dabigatran versus
warfarin. Individual difference in stroke risk for dabigatran 110mg and 150mg versus
warfarin was -0.78% ± 0.95% and -1.32% ± 1.31% and the difference in major bleeding
risk was -1.12% ± 1.44% and -0.41% ± 2.39%, respectively.

These findings demonstrate heterogeneity of treatment effect in the RE-LY trial, and the
ability of multivariate risk models to identify distinct treatment risks for individual
patients. Such models could be used in clinical practice provide patients and clinicians
with individualized treatment risk information and improve treatment decisions.
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Introduction

In 1970, the famous Boston Red Sox hitter Ted Williams, known best for his
extraordinary and yet untouched record .408 batting average, published “the science of
hitting,” a book to teach boys and girls across America how to consistently hit a
baseball.a He demonstrated the first rule of hitting, “get a good ball to hit,” through an
illustration of the strike zone that showed his personal batting average for balls thrown in
different locations (1).

a

Note the author is a fan of the 27-Time World Champion New York Yankees, not the Boston Red Sox
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The purpose of this diagram was to show that every individual should calculate their own
unique batting average for pitches in different locations, so they could swing at those
pitches where they had a high average, and avoid pitches where they didn’t hit as well.
The notion that one size doesn’t fit all, and that unique statistical profiles can inform
individualized hitting styles, was one of the earliest and most provocative displays of the
power of infusing the art of hitting, with science.

In his 2015 State of the Union Address, President Barack Obama launched the Precision
Medicine Initiative, with the mission of advancing Medicine from “on-size-fits-all”
treatments to more individualized approaches. Underlying this initiative, is the premise
that while treatments are generally developed for the “average patient,” most patients are
not in fact, average (2). The urgency of this initiative is brought on by a recognition that
Medicine is in an age of increasing availability of data from sources such as genomic
profiles, advanced diagnostic imaging, wearable devices, and clinical records in
electronic health records. This data presents the opportunity to create unique patient
profiles that can guide personalized treatment decisions, and to achieve an age of
“precision medicine.”(3) The use of such profiles has the potential to enhance both the
science and the art of Medicine. In this Thesis, I evaluate the potential to use multivariate
predictive risk models, to create individualized patient treatment risk and benefit profiles,
that can be used by clinicians and patients to make more personalized treatment
decisions.
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The application of traditional randomized trials to clinical practice and the limitation of
subgroup analyses

Randomized controlled trials are the gold standard for evaluating the effectiveness of
medical treatments. These trials are designed such that their results are generalizable, and
can inform treatment decision for broad populations of patients. Results are usually
reported as an overall treatment effect, defined as the average effect observed among all
enrolled patients. However, a major limitation of this practice, is that the average effect
may be heavily influenced by a subset of the population that has large treatment effect,
even if much of the population saw no treatment effect (4). In practice, clinicians need to
figure out how to apply these average results to individual patients, each with their own
distinct comorbidities and demographics, and consequently, potentially different risks.
Clinical investigators commonly address this challenge by publishing subgroup analyses,
through which patients are categorized according to an individual variable, and results are
published for each patient subgroup. For example, a given trial might publish the results
of an antihypertensive for men and for women, for people over the age of 65 and people
under the age of 65, or people with diabetes and people without diabetes.

While these subgroup analyses can be helpful, they face a number of challenges. First,
they have statistical limitations. They often have very limited statistical power and
consequently are subject to false negatives. Additionally, as the number of subgroups
increases, false positives will increase and reliability will subsequently decrease. Burke et
al explains the issue of false positive findings in subgroup analyses, through the analogy
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of ordering diagnostic testing for patients with and without an indication. Following
Bayes’ rule, positive findings in the group without an indication for testing, are more
likely to be false positives, than if they were found in the group who had an indication.
Similarly, adding numerous subgroup analyses to a research study, without strong
hypotheses for each analysis, is likely to lead to false positive findings (5). Last,
subgroup analyses, are limited to analyzing populations by categorical variables, and are
unable to take full advantage of continuous data such as age or blood pressure (4).

Second, subgroup analyses can pose dilemmas for individual treatment decision making,
especially given their usual reporting of hazard ratios, or relative risk reduction without
corresponding information about pre-treatment risk, or absolute risk reduction. For
example, suppose a clinical trial compared anticoagulants A and B for stroke prevention
in atrial fibrillation, and found drug A to be associated with lower rates of stroke for
people over the age of 65, and drug B to be associated with lower rates of stroke for
people with diabetes. In such a scenario, how do a 70-year-old diabetic patient and her
physician determine which medication would be best? To answer this question, the
physician and the patient need to know whether the absolute benefit of stroke prevention
of drug A is larger than the absolute benefit of drug B. And to determine this absolute
benefit, we need to know the relative risk reduction with drug A and drug B, and the pretreatment risk of their populations. For example, if the 10-year pre-treatment risk of
stroke in the 65 years and older population is 10%, and drug A showed a 50% reduction
in stroke, then the absolute decrease in stroke risk from using drug A is 5%. On the other
hand, if the 10-year pretreatment risk of stroke in the diabetic population is 1%, then a
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similar 50% risk reduction in using drug B, translates into a 0.5% absolute reduction in
risk. In this case, the patient and clinician would likely choose drug A given the absolute
risk reduction of 5% compared to the alternative absolute risk reduction of 0.5% (5).

For simplicity, the scenario above compares the benefits of two drugs. However, also
common that patients and clinicians need to weigh the benefits of an individual drug
versus the risks of that same drug. For example, patients considering anticoagulation
generally need to weigh the benefit of stroke or embolus prevention against the risk of
major bleeding. In these situations, the absolute risk of the medical event trying to be
prevented (the benefit) needs to be compared to the absolute risk of an adverse event (the
risk). This decision-making exercise will identify patients for whom the benefit of a given
treatment far outweigh the risks, as well as patients for whom the risks far outweigh the
benefits. If, for simplicity, we assume the absolute risk of adverse events is the same
across all patients, then this decision is based purely on the degree of benefit each patient
will realize. And if the relative benefit is the same for all patients, then their absolute
benefit from the treatment is simply a function of their pre-treatment risk (4). For
example, an anticoagulant that carries an identical absolute risk of bleeding for all
patients, and carries an identical relative risk reduction in stroke for all patients, might
only be appropriate for patients who have a very high pre-treatment risk of stroke, as they
will see a very large absolute benefit from treatment. For those patients who have a very
small pre-treatment risk of stroke, the absolute benefit would be smaller, and might not
outweigh the absolute risk. Thus, one of the simplest ways to determine if somebody
should receive treatment that is associated with adverse events, is to identify their pre-
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treatment risk, in order to estimate the potential absolute benefit of treatment. Such is the
rationale behind the CHADS and CHADSVASC2 scores to identify patients with the
highest pre-treatment risk, and therefore the greatest potential benefit from
anticoagulation. A similar exercise can be done to estimate the pre-treatment risk of an
adverse event, and thus to predict the absolute risk of the adverse event occurring with
treatment (4).

However, the absolute benefit or risk of a treatment is also a function of relative risk. And
relative risk is not necessarily uniform across a population. There may be specific groups
of patients who have a particularly high relative risk or a particularly high relative benefit
associated with a given treatment. The importance of identifying these different subsets
of patients, highlights another limitation of subgroup analyses.

The third challenge facing subgroup analyses the difficulty in defining a subgroup. In
some cases, subgroup definitions are clear. For example, it is known that the HER2
receptor plays a key role in the mechanism of action of Trastuzumab, and it would thus
make sense to build patient subgroups based on the genetic HER2 characteristic. In such
scenarios, in which a subgroup characteristic is clearly a part of a drug’s mechanism of
action, the use of subgroup analyses are appropriate (4). However, the appropriate
definition of a subgroup is not always as clear, and as a result, the usefulness of subgroup
analyses is limited. For example, in a study of an anticoagulant, it is difficult to determine
whether a subgroup age cutoff should be 65 versus 70 versus 75. It is possible for
example, that the particular group of people who are 75 years and older and have
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diabetes, have a uniquely great risk reduction from using drug A, or that those who are
below 40 years old and do not have diabetes have a particularly strong risk of bleeding.
These findings however, would be missed from a clinical trial that made one subgroup
based on age greater than 65, and another subgroup based on the presence of diabetes. A
similar scenario was seen in the GUSTO trial, which in 1993 found that patients
benefited from tPA relative to streptokinase for acute myocardial infarction, and in the
subgroup analysis did not find the benefit to be limited to any specific population (6).
However, in 2002, Kent et al re-analyzed the GUSTO data using newly developed riskstratification tools, to predict those patients who would benefit most from treatment, and
found that nearly all of the treatment benefits were seen among approximately 50% of
patients who were predicted to benefit the most (7). This implied that the approximately
50% of patients with the lower predicted benefits, saw little to no benefit from treatment,
and given that they still faced the drug risk of bleeding, should not be given the drug in
clinical practice (4).

Given that subgroup analyses are subject to statistical limitations, conflicting relative risk
information from different subgroups, and sub-optimal definition of subgroups, a number
of authors have proposed greater use of multivariate risk prediction models.
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Multivariate Risk Prediction Models

Netflix, one of the most popular users of multivariate risk prediction models, is wellknown for its ability to successfully provide individual subscribers with a personalized
list of “shows you might like.” Netflix could decide which show to recommend to a given
subscriber by looking at their entire subscriber base and studying the ratings of “The
Crown” versus “Mad Men,” and then recommend one of these shows to all subscribers
accordingly. Or, they could make a recommendation to a subscriber based on whether or
not they were over or under the age of 65, study “The Crown” versus “Mad Men” for
these two age based subgroups, and recommend one of the shows accordingly. However,
instead of relying on broad studies to predict subscriber preferences, Netflix has
developed multivariate risk prediction models, that make use of individualized
information captured from every subscriber, such as the genre of shows they watch, and
the time of day they watch them, and the speed with which they finish them. With this
information, Netflix can develop a multivariate predictive risk model that can classify
that subscriber, and precisely predict the which show they will enjoy watching next.

Given the massive amount of data collected from clinical research, genetic and clinical
registries, wearable devices, and electronic health records, there is great potential for
multivariate risk prediction models in healthcare to identify individual patients who
would benefit from specific therapeutics and specific doses. While multivariate models
are just one of many strategies to learn from big data, they are an important step towards
a world in which a 56 year-old man with diabetes goes into his primary care doctors
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office, where the physical activity data from his wearable watch, his daily glucometer
readings, his HbA1C from the lab, his other medications from the pharmacy, and
information about his other comorbidities, his weight and vital signs and his genetic
profile, are all fed into an algorithm that highlights his precise individual risks and
benefits from using metformin versus pioglitazone (8).

There should still be a role for “one-size-fits-all” treatment approaches for diseases that
are highly prevalent, and have treatments that are highly effective, with minimal risk (9).
However, for diseases in which multiple treatment options provide different treatment
benefits and different risks of significant adverse events, a precision approach is
warranted.

The multivariate risk prediction model has proposed as a method through which the
variety of baseline and outcome data, categorical and continuous, can be used to predict
patients’ individual risks and benefits with a given treatment (4). Multivariate models are
generally produced by developing a multivariable linear regression model, and refining
the model, by adding or removing variables, in order to strengthen its predictive
capabilities (10). Such a model, will produce a risk formula in the format of Y (risk) = b0
+ X1b1 + X2b2 where b0 is the model’s intercept, b1-2 are coefficients 1 and 2, and X1-2 are
the patients variables. For continuous variables, the value of the variable is entered in the
model. For categorical variables, the value of 1 or 0 is entered in the model, depending on
whether that variable is or is not applicable to the patient.

15

To test the theory that multivariate risk models can improve clinical research, and
identify a heterogeneity of treatment effect, recent studies have applied new multivariate
risk prediction models to completed clinical trials. Salisbury et al assessed the TRITONTIMI-38 trial which compared prasugrel v. clopidogrel, and developed a multivariate risk
prediction model to determine whether there was heterogeneity of treatment effect, not
seen in the original trial analysis. They found significant heterogeneity in the both the
risks and benefits of clopidogrel and prasugrel for different patients (11). Kernan et al
similarly re-analyzed the IRIS trial of pioglitazone after TIA and stroke, and using two
risk models developed from the IRIS data, and one external model, also found
heterogeneity (12).

Our study applies a similar principle to the RE-LY trial of Warfarin versus Dabigatran for
stroke prevention in patients with atrial fibrillation in order to assess the extent to which
different patients face different risks and benefits with each treatment.
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The RE-LY Trial

Across the United States, atrial fibrillation (AF) affects 2.7-6.1 million people, and its
prevalence is expected to increase to 5.6-12 million by 2050 (13). AF is a cardiac
arrhythmia, described clinically as an irregularly irregular heart beat due to irregular
electrical conduction from the sinoatrial node. This irregular heart rhythm impedes the
regular rhythmic output of blood from the heart, and subsequent stasis of blood can lead
to development of blood clots in the left atrial appendage. These clots can dislodge, and
emboli can enter the cerebral vasculature, and cause a stroke. Due to this
pathophysiology, people with AF have a 5 times increased risk for stroke (14).

To prevent stroke, AF is generally controlled with rate control and anticoagulation.
Anticoagulation with warfarin, an oral vitamin K antagonist, has historically been the
mainstay of treatment, but given the development of Novel Oral Anticoagulants
(NOACs), there are now more options for anticoagulation.

While warfarin is an effective treatment for AF, its administration carries substantial
lifestyle burdens that can decrease patients’ quality of life and decrease adherence. First,
patients taking warfarin cannot eat foods that have significant amounts of vitamin K such
as spinach or kale, as warfarin’s mechanism of action is to antagonize vitamin K. Second,
patients who take warfarin need to have their blood INR monitored through regular blood
draws, and their warfarin dose adjusted accordingly, in order to ensure a therapeutic PT
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and INR, that is sufficient to prevent stroke, but not too high as to increase risk of
hemorrhage.

The development of non-vitamin K oral anticoagulants, the anti-X inhibitors apixaban
and rivaroxaban and the direct thrombin inhibitor dabigatran, were developed as
attractive alternative anticoagulants to warfarin, as they reduce the burden of dietary
restrictions and need for frequent blood monitoring. The lifestyle benefits of these
medications however, need to be weighed against their clinical effectiveness, and
numerous trials have compared the non-vitamin K oral anticoagulants versus warfarin for
different clinical conditions (15-17).
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Statement of Purpose and Hypothesis

Our study focuses on the RE-LY trial which compared warfarin versus dabigatran in AF
for the prevention of stroke (15). The RE-LY trial, conducted in 2009, included 18,113
patients with AF who were deemed to be at increased risk of stroke. This increased risk
of stroke was defined by factors such as a history stroke or Transient Ischemic Attack,
age or the presence of diabetes mellitus. Exclusion criteria included patients with an
increased risk for hemorrhage, a recent or severe stroke and active liver disease (15).
Patients were randomized to receive either warfarin, dabigatran 110mg BID or dabigatran
150mg BID. Patients were blinded to their dose of dabigatran, however, were not blinded
to receiving warfarin, as blood INR needed to be monitored and warfarin doses adjusted
in order to maintain an INR of 2.0 to 3.0. Patients were assessed for two primary
outcomes: the presence of stroke or systemic embolism, and the presence of major
bleeding. Other outcomes included myocardial infarction, pulmonary embolism and GI
bleeding. The study concluded after 5 years, and found the annual rate of stroke to be
1.69% for warfarin, 1.53% for dabigatran 110mg and 1.11% for dabigatran. The annual
rate of major bleeding was 3.36% for warfarin, 2.71% for dabigatran 110mg and 3.11%
for dabigatran 150mg. The analysis demonstrated that dabigatran 110mg was associated
with similar rates of stroke and systemic embolism compared to warfarin, and a
significantly lower rate of bleeding. Dabigatran 150mg BID was associated with lower
rates of stroke and systemic embolism than warfarin, and a similar rate of bleeding.
However, dabigatran 150mg, was associated with a higher rate of gastrointestinal
bleeding (15).
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While the RE-LY trial subgroup analyses did not reveal significant differences in
treatment effect, we sought to determine whether an analysis of the data with multivariate
risk models would reveal heterogeneity of treatment effect (15). Using the RE-LY data,
we developed two multivariate predictive risk models and assessed individual patients’
risks of stroke or systemic embolism and their risk of bleeding, if they were treated
warfarin, dabigatran 110mg BID or dabigatran 150mg BID. We then sought to determine
whether there were differences individual patients’ predicted risks and benefits with each
treatment.

The hypothesis of this analysis, is that there is significant heterogeneity of treatment
effect with dabigatran versus warfarin, regarding the risk of stroke or systemic embolism,
and the risk of major bleeding among the RE-LY population. This hypothesis is tested
through the development of a multivariate model, and the subsequent application of that
model to the RE-LY data to assess the degree of heterogeneity of treatment among the
RE-LY population.

The presence of such a heterogeneity of treatment effect would demonstrate the need to
use such a multivariate predictive risk models to aid in day to day clinical decisions
regarding warfarin versus different doses of dabigatran for stroke prevention in AF, and
would also demonstrate the benefit of using similar models in clinical research going
forward.
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Methods

Population

The RE-LY trial included 18,113 patients with AF who were at increased risk for stroke
(15). Over the 2-year study period, patients were given either warfarin at a titrated dose to
achieve an INR of 2.0-3.0, dabigatran 110mg twice a day, or dabigatran 150mg twice a
day. Patients were regularly monitored for the presence of the primary outcomes of stroke
or systemic embolism or major bleeding, as well as for secondary outcomes including
pulmonary embolism, myocardial infarction and gastrointestinal bleeding. To be included
in the study, patients were required to have a documented history of AF in the past 6
months, as well as an increased risk of stroke, evidenced by a history of stroke or
Transient Ischemic Attack, NYHA class II heart failure symptoms, reduced Left
Ventricular Ejection Fraction, age greater than 75, or age 65-74 and the presence of
hypertension, coronary artery disease or diabetes mellitus. Patients were excluded from
the study if they had an increased risk of hemorrhage, a stroke within the past 15 days, a
severe stroke in the past 6 months, a severe heart valve disorder, pregnancy, active liver
disease or low creatinine clearance (15). Our study includes all patients who were
included in the RE-LY trial and completed a 2-year course of warfarin, dabigatran 110mg
BID or dabigatran 150mg. No additional exclusions were applied.
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Outcome

The primary outcomes of both the RE-LY trial, and this study are stroke or systemic
embolism and major bleeding, representing the major benefits and risks of
anticoagulation in patients with AF and a risk of stroke.

Statistical Analyses

Using the data from the RE-LY trial, we developed two multivariate predictive risk
models for the two primary outcomes of stroke or systemic embolism and major
hemorrhage. Our models were built on the methodological framework developed by
Salisbury et al in their analysis of the TRITON-TIMI-38 study data (11). To construct
each model, we fit a multivariable linear regression model using all variables that we
deemed to be potentially relevant to the outcomes, based on prior research as well as the
clinical experience of the authors. We then worked to minimize the number of variables
in the model in order to make the models easier to use in the clinical setting. We used the
Harrell backwards selection method to the models, to remove variables sequentially, until
all variables retained in the model had at least a 5% contribution to the model’s predictive
capacity (10). The included and excluded variables, and the order in which they were
excluded are listed in Table 2, with their corresponding degree of contribution to the
model. For each model, we calculated the discrimination (c-statistic) and calibration
(Hosmer-Lemeshow, and used restricted cubic splines to assess the assumption that the
continuous variables were linearly associated with the outcomes (18).
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To assess for heterogeneity of the benefits and risks of each treatment, we applied the risk
models to every patient in the RE-LY trial, first assuming they were treated with
warfarin, a second time assuming they were treated with dabigatran 110mg, and a third
time assuming they were treated with dabigatran 150mg. To characterize the populationlevel heterogeneity of treatment effect, we determined for each treatment, the mean risk
and standard deviation of stroke or systemic embolism and the mean risk of major
hemorrhage. To characterize the individual-level heterogeneity of treatment effect, we
calculated the absolute difference in risk or benefit between warfarin and dabigatran
110mg, and warfarin and dabigatran 150mg. Specifically, the absolute difference in the
risk of stroke or systemic embolism was calculated as each patients’ risk if they were
treated with dabigatran 110mg minus their risk if they were treated with warfarin, and as
their risk if they were treated with dabigatran 150mg minus their risk if they were treated
with warfarin. Similarly, the absolute difference in the risk of major hemorrhage is
calculated as each individual’s risk of major hemorrhage with dabigatran 110mg minus
their risk with warfarin, and their risk with dabigatran 150mg minus their risk with
warfarin. We report a density plot to demonstrate the range of absolute differences
between dabigatran 110mg and warfarin, and dabigatran 150mg and warfarin.

We report categorical variables as frequencies, and continuous variables as medians with
interquartile ranges.

All analyses were conducted using R version 3.3.1 and SAS version 9.3.
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The initial statistical model was based on the model described by Salisbury et al, and the
model development was conducted by Sophie Tang, at Saint Luke’s Mid America Heart
Institute, with a research group led by Dr. John Spertus (11). Dr. Nihar Desai and I
worked closely together to interpret the statistical output for clinical relevance, and
worked closely with Sophie Tang to determine the data output most relevant to the
hypothesis and project.

For example, I proposed that we create “mock patients” based on the model, and worked
with Dr. Desai and Sophie Tang to develop a risk calculator, based on the model output.
And using this model, I created the mock patients that are included in the thesis as part of
the two decision aids.
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Results

A total of 18,040 patients were included in the analysis, 5,983 of whom were assigned to
dabigatran 110mg in the RE-LY trial, 6,059 of whom were assigned to dabigatran
150mg, and 5,998 of whom were assigned to warfarin. The median age was 71.4 ± 8.6
and 3.6% of participants were male. The ethnicity of the subjects, was 15.9% Asian,
1.0% Black, 70.0% White, and 13.1% Other. The distribution of AF types of paroxysmal,
permanent and persistent were 32.8%, 35.2% and 32.0%, respectively. Baseline
characteristics included heart failure (32.0%), hypertension (78.8%), diabetes mellitus
(23.3%) and stroke/systemic embolism/TIA (21.8%). As seen in Table 1, demographic
and baseline characteristics were similar among all three treatment groups.
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Table 1: Baseline Characteristics
Treatment Pattern Label
Dabigatran 110mg BID Dabigatran 150mg BID
n = 5983
n = 6059

Total
Warfarin
n = 5998

n = 18040

Age
Mean ± SD
Median (IQR)

0.693
71.3 ± 8.6
72.0 (67.0, 77.0)

71.4 ± 8.7

71.5 ± 8.5

71.4 ± 8.6

72.0 (67.0, 78.0) 72.0 (67.0, 77.0) 72.0 (67.0, 77.0)

Age Grouping

0.121

<40

21 (0.4%)

26 (0.4%)

12 (0.2%)

59 (0.3%)

40<= and <50

99 (1.7%)

86 (1.4%)

89 (1.5%)

274 (1.5%)

50<= and <65

873 (14.6%)

916 (15.1%)

849 (14.2%)

2638 (14.6%)

65<= and <75

2655 (44.4%)

2574 (42.5%)

2635 (43.9%)

7864 (43.6%)

>=75

2335 (39.0%)

2457 (40.6%)

2413 (40.2%)

7205 (39.9%)

Sex
Female

0.323
2130 (35.6%)

2228 (36.8%)

2202 (36.7%)

6560 (36.4%)

Ethnicity

0.871

Asian

948 (15.8%)

961 (15.9%)

955 (15.9%)

2864 (15.9%)

Black

51 (0.9%)

57 (0.9%)

66 (1.1%)

174 (1.0%)

White

4191 (70.0%)

4258 (70.3%)

4181 (69.7%)

12630 (70.0%)

Other

793 (13.3%)

783 (12.9%)

796 (13.3%)

2372 (13.1%)

Region

0.999

Asia

918 (15.3%)

929 (15.3%)

926 (15.4%)

2773 (15.4%)

Central Europe

703 (11.7%)

704 (11.6%)

706 (11.8%)

2113 (11.7%)

Latin America

319 (5.3%)

319 (5.3%)

316 (5.3%)

954 (5.3%)

USA, Canada

2150 (35.9%)

2195 (36.2%)

2152 (35.9%)

6497 (36.0%)

Western Europe

1541 (25.8%)

1552 (25.6%)

1543 (25.7%)

4636 (25.7%)

352 (5.9%)

360 (5.9%)

355 (5.9%)

1067 (5.9%)

Other
AF Type

0.104

Paroxysmal

1916 (32.0%)

1974 (32.6%)

2030 (33.9%)

5920 (32.8%)

Permanent

2123 (35.5%)

2183 (36.0%)

2045 (34.1%)

6351 (35.2%)

Persistent

1941 (32.5%)

1901 (31.4%)

1922 (32.0%)

5764 (32.0%)

2384 (39.8%)

2338 (38.6%)

2431 (40.5%)

7153 (39.7%)

Aspirin at baseline

0.086

CHADS2 Score
Mean ± SD
Median (IQR)

0.666
2.1 ± 1.1

2.2 ± 1.1

2.1 ± 1.1

2.1 ± 1.1

2.0 (1.0, 3.0)

2.0 (1.0, 3.0)

2.0 (1.0, 3.0)

2.0 (1.0, 3.0)

CHADS2 Score
0

PValue

0.221
151 (2.5%)

145 (2.4%)

155 (2.6%)

451 (2.5%)
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Treatment Pattern Label
Dabigatran 110mg BID Dabigatran 150mg BID
n = 5983
n = 6059

Total
Warfarin
n = 5998

n = 18040

1

1797 (30.0%)

1810 (29.9%)

1705 (28.4%)

5312 (29.4%)

2

2081 (34.8%)

2129 (35.1%)

2212 (36.9%)

6422 (35.6%)

3+

1954 (32.7%)

1975 (32.6%)

1926 (32.1%)

5855 (32.5%)

History of Heart Failure

PValue

0.889
1929 (32.2%)

1930 (31.9%)

1915 (31.9%)

5774 (32.0%)

Baseline Heart Failure
Classification

0.268

NYHA I

293 (15.2%)

292 (15.1%)

295 (15.4%)

880 (15.3%)

NYHA II

1222 (63.4%)

1195 (62.0%)

1219 (63.7%)

3636 (63.0%)

NYHA III

383 (19.9%)

400 (20.7%)

352 (18.4%)

1135 (19.7%)

NYHA IV

30 (1.6%)

41 (2.1%)

48 (2.5%)

119 (2.1%)

LVEF

0.723

<=40%

647 (22.0%)

651 (21.9%)

628 (21.2%)

1926 (21.7%)

Baseline Hypertension

0.974

Requiring Medical Treatment
4711 (78.7%)

4781 (78.9%)

4729 (78.8%)

14221 (78.8%)

1401 (23.4%)

1398 (23.1%)

1405 (23.4%)

4204 (23.3%)

History of Diabetes Mellitus

0.872

History of Stroke/Systemic
Embolism/TIA

0.389

1302 (21.8%)

1357 (22.4%)

1282 (21.4%)

3941 (21.8%)

Baseline Creatinine
Clearance [mL/min]
Mean ± SD
Median (IQR)

0.846
73.0 ± 27.7
68.7 (53.2, 87.2)

72.8 ± 28.2

73.0 ± 27.4

72.9 ± 27.8

67.9 (53.0, 86.4) 68.5 (53.8, 86.6) 68.4 (53.4, 86.8)

Creatinine Clearance
<30

0.044
14 (0.2%)

31 (0.5%)

29 (0.5%)

74 (0.4%)

30<= and <50

1127 (19.7%)

1152 (19.7%)

1048 (18.2%)

3327 (19.2%)

50<= and <80

2705 (47.2%)

2770 (47.5%)

2794 (48.7%)

8269 (47.8%)

>=80

1889 (32.9%)

1880 (32.2%)

1872 (32.6%)

5641 (32.6%)

82.9 ± 19.9

82.4 ± 19.3

82.6 ± 19.6

82.7 ± 19.6

Weight [kg]
Mean ± SD
Median (IQR)

0.385

80.5 (70.0, 94.0)

80.0 (69.0, 93.0) 80.0 (70.0, 93.0) 80.0 (69.9, 93.4)

Continuous variables compared using one-way analysis of variance.
Categorical variables compared using chi-square or Fisher's exact test.
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As seen in Table 2, patients who took warfarin had the highest rate of stroke (2.1%) and
major bleeding (4.7%). Patients who took dabigatran 150mg had the lowest risk of stroke
(0.9%), and patients who took dabigatran 110mg had the lowest rate of major bleeding
(3.6%).

Table 2: Outcomes
Treatment Pattern Label
Dabigatran 110mg bid Dabigatran 150mg bid
n = 5983
n = 6059

Warfarin
n = 5998

Total

P-Value

n = 18040

Stroke/Systemic Embolism

< 0.001

84 (1.4%)

53 (0.9%) 125 (2.1%) 262 (1.5%)

Major Bleeding

0.011
216 (3.6%)

261 (4.3%) 281 (4.7%) 758 (4.2%)

To build the predictive risk models for ischemic stroke or systemic embolism and major
bleeding, we used prior literature and clinical expertise, to choose 15 variables that could
contribute to the risk of stroke or systemic embolism, and 16 variables that could
contribute to the risk of major bleeding. We then conducted two multivariate logistic
regressions using all of these 15 variables for stroke and 16 variables for major bleeding.
The variables in this model and their analysis of effects are shown in Tables 3-A and 3-B.
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Table 3-A: Logistic Full Model: Stroke or Systemic Embolism

Type 3 Analysis of Effects

DF

Wald
ChiSquare

Pr > ChiSq

Treatment Pattern

2

9.5803

0.0083

Age

1

0.0413

0.8389

Weight

1

0.8192

0.3654

Sex

1

0.9691

0.3249

Region

4

4.4377

0.3500

Aspirin at Baseline

1

0.0236

0.8778

AF Type

2

2.0821

0.3531

Baseline Heart
Failure

1

0.8617

0.3533

Baseline
Hypertension

1

1.0227

0.3119

Baseline Diabetes
Mellitus

1

13.1876

0.0003

Baseline
Stroke/Embolus/TI
A

1

28.1507

<.0001

Creatinine
Clearance

1

6.3709

0.0116

Age * Treatment
Pattern

2

6.7463

0.0343

Baseline Diabetes
Mellitus *
Treatment Pattern

2

4.4426

0.1085

Creatinine
Clearance *
Treatment Pattern

2

9.8738

0.0072

Effect
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Table 3-B: Logistic Full Model: Major Bleeding

Type 3 Analysis of Effects
Effect

Wald
DF Chi-Square

Pr > ChiSq

Treatment
Pattern

2

27.7766

<.0001

Age

1

1.0372

0.3085

Weight

1

0.7499

0.3865

Sex

1

1.5558

0.2123

Region

4

54.7331

<.0001

Aspirin at
Baseline

1

8.3936

0.0038

AF Type

2

3.7635

0.1523

Baseline Heart
Failure

1

0.5020

0.4786

Baseline
Hypertension

1

1.6975

0.1926

Baseline Diabetes
Mellitus

1

11.1931

0.0008

Baseline
Stroke/Embolus/
TIA

1

4.9456

0.0262

Creatinine
Clearance

1

36.0031

<.0001

Age * Treatment
Pattern

2

19.5937

<.0001

Weight *
Treatment
Pattern

2

14.1518

0.0008

Treatment
Pattern * AF
Type

4

6.4746

0.1664

Baseline Heart
Failure *
Treatment
Pattern

2

5.1824

0.0749
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To create the final predictive risk models, we used the Harrell Backwards Selection
Strategy for each model, to sequentially remove the variable that had the smallest
contribution to the model’s predictive capacity. After the removal of each variable, the
model was run again, and the process was repeated until all variables had a p value of less
than 0.2. Through this process, 6 variables were removed from the stroke or systemic
embolism model (Weight, Sex, Aspirin at Baseline, AF Type, Baseline Heart Failure,
Baseline Hypertension) and 2 variables were removed from the major bleeding model
(Sex, Baseline Hypertension). Tables 4-A and 4-B show the analysis of effects of the 9
variables included in the final stroke or systemic embolism risk model, and the 14
variables included in the final major bleeding risk model.

Table 4-A: Logistic Prediction Model: Stroke or Systemic Embolism

Type 3 Analysis of Effects

DF

Wald
ChiSquare

Pr > ChiSq

Treatment
Pattern

2

9.3071

0.0095

Age

1

0.0128

0.9098

Region

4

7.0768

0.1319

Baseline Diabetes
Mellitus

1

13.1932

0.0003

Baseline
Stroke/Embolus/
TIA

1

27.7175

<.0001

Creatinine
Clearance

1

9.8821

0.0017

Age * Treatment
Pattern

2

6.5125

0.0385

Effect
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Type 3 Analysis of Effects

DF

Wald
ChiSquare

Pr > ChiSq

Baseline Diabetes
Mellitus *
Treatment
Pattern

2

4.2451

0.1197

Creatinine
Clearance *
Treatment
Pattern

2

9.6253

0.0081

Effect

Table 4-B: Logistic Prediction Model: Major Bleeding
Type 3 Analysis of Effects

DF

Wald
ChiSquare

Pr > ChiSq

Treatment
Pattern

2

27.5394

<.0001

Age

1

1.0161

0.3135

Weight

1

1.6399

0.2003

Region

4

54.7754

<.0001

Aspirin at
Baseline

1

8.9961

0.0027

AF Type

2

3.9765

0.1369

Baseline Heart
Failure

1

0.4419

0.5062

Baseline Diabetes
Mellitus

1

11.7785

0.0006

Baseline
Stroke/Embolus/
TIA

1

4.9358

0.0263

Creatinine
Clearance

1

37.2981

<.0001

Age * Treatment
Pattern

2

19.4564

<.0001

Effect
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Type 3 Analysis of Effects

DF

Wald
ChiSquare

Pr > ChiSq

Weight *
Treatment
Pattern

2

14.0595

0.0009

Treatment
Pattern * AF
Type

4

6.5333

0.1627

Baseline Heart
Failure *
Treatment
Pattern

2

5.3254

0.0698

Effect

Figures 1-A and 1-B demonstrate the impact of individual patient variables on the full
stroke or systemic embolism and major bleeding models respectively. For the stroke or
systemic embolism model, a history of stroke/systemic embolism/TIA (OR 2.01) and
baseline diabetes with warfarin (OR 2.00) had the largest impact on risk of stroke or
systemic embolism. Age in warfarin (OR 1.03), and whether the patient was taking
Aspirin (OR 1.02), had the smallest impact on risk of stroke or systemic embolism.
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Figure 1-A (19)

Odds Ratios: Stroke or Systemic Embolism
Study Name

OR

LCL

UCL

Male vs Female

0.87

0.66

1.15

Region: Asia vs USA, Canada

1.42

0.94

2.12

Region: Central Europe vs USA, Canada

0.87

0.52

1.4

Region: Latin, Other vs USA, Canada

1.06

0.67

1.63

Region: Western Europe vs USA, Canada

1.12

0.79

1.58

ASA

1.02

0.79

1.32

History of Hypertension

1.18

0.86

1.64

History of Stroke/SEE/TIA

2.01

1.54

2.61

Age (+10) in Dabigatran 110mg

0.87

0.65

1.16

Age (+10) in Dabigatran 150mg

1.68

1.1

2.57

Age (+10) in Warfarin

1.03

0.79

1.34

Weight (+10) in Dabigatran 110 mg

0.95

0.85

1.06

Diabetes in Dabigatran 110 mg

1.15

0.69

1.89

Diabetes in Dabigatran 150 mg

1.09

0.58

2.05

Diabetes in Warfarin

2

1.38

2.91

CrCl (+10) in Dabigatran 110mg

0.91

0.81

1.02

CrCl (+10) in Dabigatran 150mg

1.1

0.97

1.25

CrCl (+10) in Warfarin

0.87

0.78

0.97

Paroxysmal vs Persistent in Dabigatran 110 mg

0.85

0.62

1.17

Paroxysmal vs Persistent in Dabigatran 150 mg

1.07

0.79

1.45

History of Heart Failure

1.14

0.86

1.5

1

0

3

0.1

0.75

1.5

Odds Ratio (95% CI)

Odds Ratio (95% CI)

3

Graph Generated by DistillerSR

1

For the major bleeding model, history of heart failure in patients taking dabigatran 110mg
(OR 1.52), Central Europe versus USA, Canada (OR 0.46), and age in dabigatran 150mg
(OR 1.93) had the greatest impact on the risk of bleeding. History of heart failure in
dabigatran 150mg (OR 0.96) and weight in warfarin (OR 1.04) had the smallest impact
on the model.
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Figure 1-B (19)

Odds Ratios: Major Bleeding
Study Name

OR

LCL

UCL

Male vs Female

0.9

0.76

1.06

Region: Asia vs USA, Canada

0.62

0.47

0.81

Region: Central Europe vs USA, Canada

0.46

0.34

0.63

Region: Latin, Other vs USA, Canada

0.54

0.41

0.7

Region: Western Europe vs USA, Canada

0.55

0.45

0.68

ASA

1.25

1.07

1.46

Hypertension

1.14

0.94

1.4

Diabetes

1.34

1.12

1.58

History of Stroke/SEE/TIA

1.22

1.02

1.45

CrCl (+10)

0.86

0.82

0.9

Age (+10) in Dabigatran 110mg

1.57

1.27

1.93

Age (+10) in Dabigatran 150mg

1.93

1.57

2.37

Age (+10) in Warfarin

1.09

0.91

1.32

Weight (+10) in Dabigatran 110 mg

1.13

1.04

1.22

Weight (+10) in Dabigatran 150 mg

1.24

1.15

1.36

Weight (+10) in Warfarin

1.04

0.96

1.13

Paroxysmal vs Persistent AF in Dabigatran 110 mg

1.21

0.86

1.7

Paroxysmal vs Persistent AF in Dabigatran 150 mg

1.23

0.89

1.68

Paroxysmal vs Persistent AF in Warfarin

0.79

0.58

1.07

Permanent vs Persistent in Dabigatran 110 mg

1.01

0.71

1.44

Permanent vs Persistent in Dabigatran 150 mg

1.17

0.85

1.62

Permanent vs Persistent AF in Warfarin

1.05

0.78

1.41

History of Heart Failure in Dabigatran 110 mg

1.52

1.14

2.05

History of Heart Failure in Dabigatran 150 mg

0.96

0.72

1.28

History of Heart Failure in Warfarin

1.1

0.84

1.45

1

0

3

0.1

0.75

1.5

3

Graph Generated by DistillerSR

1

The final multivariate predictive risk models for stroke or systemic embolism and major
bleeding are presented in Tables 5-A and 5-B. The estimates for stroke or systemic
embolism show the value of the intercept at -3.3677, and the estimates for major bleeding
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show the value of the intercept at -2.8732. The Tables also show the estimates of the
regression coefficients for each variable included in the final stroke model or bleeding
model. Using these models, the risk of stroke or systemic embolism and the risk of major
bleeding can be calculated for any patient based on the equation Y (risk) = b0 + X1b1 +
X2b2 + X3b3 + X4b4, where b0 is the model’s intercept, b1-4 are the model’s regression
coefficients, and X1-4 are the variables, defined as either 0 or 1 based on the absence or
presence of the variable.

Table 5-A: Logistic Prediction Model: Stroke or Systemic Embolism
Analysis of Penalized Maximum Likelihood Estimates
Wald
ChiSquare

Pr > ChiSq

DF

Estimate

Standard
Error

Intercept

1

-3.3677

1.2175

7.6507

0.0057

Treatment Pattern A

1

0.6235

1.7072

0.1334

0.7150

Treatment Pattern B

1

-5.9296

2.1931

7.3100

0.0069

Age

1

0.00154

0.0136

0.0128

0.9098

Parameter

Region

Asia

1

0.4461

0.1831

5.9386

0.0148

Region

Central Europe

1

-0.0432

0.2414

0.0321

0.8579

Region

Latin, Other

1

0.1238

0.2175

0.3241

0.5691

Region

Western Europe

1

0.1419

0.1706

0.6924

0.4053

Baseline Diabetes
Mellitus

1

0.6902

0.1900

13.1932

0.0003

Baseline
Stroke/Embolus/TI
A

1

0.6961

0.1322

27.7175

<.0001

Creatinine
Clearance

1

-0.0157

0.00498

9.8821

0.0017

Age * Treatment
Pattern

A

1

-0.0164

0.0196

0.6982

0.4034

Age * Treatment
Pattern

B

1

0.0495

0.0252

3.8623

0.0494

Baseline Diabetes
A
Mellitus *
Treatment Pattern

1

-0.5543

0.3184

3.0300

0.0817

36

Analysis of Penalized Maximum Likelihood Estimates
Wald
ChiSquare

Pr > ChiSq

DF

Estimate

Standard
Error

Baseline Diabetes
B
Mellitus *
Treatment Pattern

1

-0.5919

0.3759

2.4803

0.1153

Creatinine
A
Clearance *
Treatment Pattern

1

0.00430

0.00731

0.3451

0.5569

Creatinine
B
Clearance *
Treatment Pattern

1

0.0234

0.00776

9.0839

0.0026

Parameter

Table 5-B: Logistic Prediction Model: Major Bleeding
Analysis of Penalized Maximum Likelihood Estimates
Standard
DF Estimate
Error

Parameter
Intercept

Wald
ChiSquare Pr > ChiSq

1

-2.8732

0.8338 11.8757

0.0006

Treatment Pattern

A

1

-3.8326

1.1614 10.8894

0.0010

Treatment Pattern

B

1

-5.9535

1.1736 25.7353

<.0001

Age

1

0.00922

0.00915

1.0161

0.3135

Weight

1

0.00504

0.00393

1.6399

0.2003

Region

Asia

1

-0.4659

0.1383 11.3387

0.0008

Region

Central
Europe

1

-0.7622

0.1589 23.0209

<.0001

Region

Latin,
Other

1

-0.6145

0.1367 20.1987

<.0001

Region

Western
Europe

1

-0.5979

0.1054 32.1737

<.0001

1

0.2334

0.0778

8.9961

0.0027

Aspirin at Baseline
AF Type

Paroxysmal

1

-0.2440

0.1553

2.4680

0.1162

AF Type

Permanent

1

0.0521

0.1512

0.1188

0.7303

Baseline Heart Failure

1

0.0919

0.1383

0.4419

0.5062

Baseline Diabetes
Mellitus

1

0.2951

0.0860 11.7785

0.0006

Baseline
Stroke/Embolus/TIA

1

0.1996

0.0898

0.0263

4.9358
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Analysis of Penalized Maximum Likelihood Estimates
Standard
DF Estimate
Error

Parameter
Creatinine Clearance

1

-0.0152

Wald
ChiSquare Pr > ChiSq

0.00248 37.2981

<.0001

Age*Treatment
Pattern

A

1

0.0353

0.0131

7.2561

0.0071

Age*Treatment
Pattern

B

1

0.0560

0.0130 18.4606

<.0001

Weight * Treatment
Pattern

A

1

0.00834

Weight * Treatment
Pattern

B

1

0.0185

Treatment Pattern *
AF Type

A

Paroxysmal

1

0.4333

0.2319

3.4917

0.0617

Treatment Pattern *
AF Type

A

Permanent

1

-0.0351

0.2329

0.0227

0.8802

Treatment Pattern *
AF Type

B

Paroxysmal

1

0.4418

0.2233

3.9148

0.0479

Treatment Pattern *
AF Type

B

Permanent

1

0.1102

0.2217

0.2470

0.6192

Baseline Heart Failure
* Treatment Pattern

A

1

0.3297

0.2025

2.6516

0.1034

Baseline Heart Failure
* Treatment Pattern

B

1

-0.1417

0.2012

0.4962

0.4812

0.00495

2.8309

0.0925

0.00493 14.0500

0.0002

The models were tested using a bootstrapping procedure, in which the predictive model
was applied to a randomly selected subset of patients, and the model’s output, including
the predicted risk of stroke, was then compared to the true results of the entire population.
This procedure was repeated 10 times, to examine the true predictive capacity of each
model. To examine the predicted events with the bootstrapped population compared to
the true events of the population, the predicted events of the bootstrapped population
were calibrated to the true events of the full RE-LY sample population. Tables 6-A and 6B show the parameter estimates of the population which, for the slope, are 0.98356 for
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the stroke or systemic embolism model and 0.98247 for the major bleeding model, with
Pr > |t| values < .001. These results demonstrate that we can reject the null hypothesis that
the slope of the model is 0. Tables 7-A and 7-B show the test slope results with Pr>F
values of 0.8311 and 0.7318 for the stroke or systemic embolism model and major
bleeding model respectively, demonstrating that we cannot reject the null hypothesis that
the slope is 1. The proximity of the slope to 1, is demonstrated by the R-square values of
0.9560 for the stroke or systemic embolism model, and 0.9802 for the major bleeding
model. The proximity of the slope to 1 demonstrates the strength of the model’s
predictive capacity. The calibration is demonstrated graphically in Figures 2-A and 2-B,
with each event rate for each bootstrap sample against its respective population. The
proximity of the intercept towards 0 and the R-Square to 1, and the proximity of the
calibration graph to the 45-degree line, demonstrate the linearity of the calibration and
therefore the predictive strength of the model. The c-statistic, or area under the curve, is
0.675 for the stroke or systemic embolism model and 0.694 for the major bleeding model.

39

Table 6-A: Stroke or Systemic Embolism Prediction Model Calibration

Variable
Intercept
Slope

Parameter Estimates
Parameter Standard
Estimate
Error
-0.00022276
0.00136
0.98356
0.07458

DF
1
1

t Value
-0.16
13.19

Pr > |t|
0.8743
<.0001

Table 6-B: Major Bleeding Prediction Model Calibration
Table 6-B Parameter Estimates

Variable

DF

Parameter
Estimate

Standard
Error

t Value

Pr > |t|

Intercept

1

0.00009327

0.00255

0.04

0.9718

Mean

1

0.98247

0.04938

19.90

<.0001

Table 7-A: Stroke or Systemic Embolism Prediction Model Calibration
Test Slope Results for Stroke or Systemic Embolism
Source

Mean
Square F Value

DF

Numerator

1

2.833789E-7

Denominator

8

0.00000583

R-Square

0.9560

C-Statistic

0.675

0.05

Pr > F
0.8311

Table 7-B: Major Bleeding Prediction Model Calibration
Test Slope Results for Major Bleeding
DF

Mean
Square

F
Value

Pr > F

Numerator

1

0.00000251

0.13

0.7318

Denominator

8

0.00001993

Source

R-Square

0.9802

C-Statistic

0.694
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Figure 2-A
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Figure 2-B
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We then applied the predictive risk model to each patient in the RE-LY trial to assess for
heterogeneity of treatment effect of both dabigatran 110mg and 150mg versus warfarin.
The following tables show the number of patients who had a statistically significant
difference between their stroke or systemic embolism, or major bleeding risk with
dabigatran or warfarin. As seen in Tables 8-A and 8-B, 30.37% and 46.45% of patients
had statistically significant differences in their risk of stroke or systemic embolism and
major bleeding, respectively, with dabigatran 110mg versus warfarin. As seen in Tables
9-A and 9-B, 70.88% and 47.58% of patients had statistically significant differences in
stroke or systemic embolism and major bleeding risk, respectively, with dabigatran
150mg versus Warfarin.

Table 8-A
Stroke/Systemic Embolism log(odds): Dabigatran 110mg Warfarin Significance
Cumulative Cumulative
Significance Frequency Percent
Frequency
Percent
Non12562
69.63
12562
69.63
Significant
Significant

5478

30.37

18040

100.00

Table 8-B
Major Bleeding log(odds): Dabigatran 110mg - Warfarin
Significance
Significance

Frequency

Percent

Cumulative
Frequency

Cumulative
Percent

NonSignificant

9661

53.55

9661

53.55

Significant

8379

46.45

18040

100.00
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Table 9-A
Stroke/Systemic Embolism log(odds): Dabigatran 150mg Warfarin Significance
Significance

Frequency

Percent

Cumulative
Frequency

Cumulative
Percent

NonSignificant

5254

29.12

5254

29.12

Significant

12786

70.88

18040

100.00

Table 9-B
Major Bleeding log(odds): Dabigatran 150mg - Warfarin
Significance
Significance

Frequency

Percent

Cumulative
Frequency

Cumulative
Percent

NonSignificant

9457

52.42

9457

52.42

Significant

8583

47.58

18040

100.00

It is important to note however, that the frequency of patients who had a statistically
significantly different risk with dabigatran versus warfarin, includes both patients with an
increased risk and patients with a decreased risk. Figures 3 and 4 demonstrate the
distribution of this risk, distinguishing patients with and without a statistically significant
difference by color and distance from the fit line, and by whether they had an increased
or decreased risk, by position above or below the fit line, respectively, with dabigatran. In
Figure 3-A for example, all patients who had a statistically significant risk of stroke or
systemic embolism with dabigatran 110mg, had a decreased risk. With regard to bleeding
risk in Figure 3-B however, while most patients had a decreased risk with dabigatran
110mg, some patients had an increased risk. The greatest distribution between increased
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and decreased risk is seen in Figure 4-B, which demonstrates that many patients had a
decreased risk of bleeding with dabigatran 150mg, and many patients that had an
increased risk of bleeding.

Figures 3A-3B: Dabigatran 110mg - Warfarin Significance
Figure 3-A

Figure 3-B

Strokse: log(Odds) A-C

M ajorb: log(Odds) A-C
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Figures 4A-4B: Dabigatran 150mg - Warfarin Significance
Figure 4-A

Figure 4-B

Strokse: log(Odds) B-C
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To further examine the heterogeneity of treatment effect, we put each patient through the
model to determine their risk of stroke or systemic embolism and risk of major bleeding
with dabigatran 110mg, dabigatran 150mg, and warfarin. We then calculated the
differences in these risks as risk of stroke or systemic embolism with dabigatran minus
risk of stroke or systemic embolism with warfarin, and risk of major bleeding with
dabigatran minus risk of major bleeding with warfarin. As seen in Table 10, the mean
difference of risk between dabigatran 110 and Warfarin was -0.78% ± 0.95% for stroke
or systemic embolism and -1.12% ± 1.44% for major bleeding. The mean difference of
risk between dabigatran 150mg was -1.32% ± 1.31% for stroke or systemic embolism
and -0.41% ± 2.39% for major bleeding. These ranges of risk differences for dabigatran
110mg and 150mg versus warfarin are demonstrated graphically in Figures 5-6. All areas
of the curves to the left of 0, represent those patients with a smaller risk of stroke or
systemic embolism, or major bleeding with dabigatran, and all areas to the right of the
curves represent those patients with a smaller risk of stroke or systemic embolism or
major bleeding risk with warfarin. The fact that all curves cross the zero line
demonstrates the range of treatment superiority with regard to a given risk. The width of
the curves, particularly with regard to major bleeding demonstrates the range of benefits
for different patients of using one anticoagulant versus the other.
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Table 10: Logistic Predictive Probability Difference between Dabigatran and
Warfarin
Logistic Predictive
Probability
Difference of:

N

Mean Std Dev Minimum Maximum

STROKSE:
Dabigatran 110mg Warfarin

17237 -0.0077530 0.0095157

-0.0932936

0.0215243

Major Bleeding:
Dabigatran 110mg Warfarin

17226 -0.0112073 0.0143663

-0.0776957

0.2324420

STROKSE:
Dabigatran 150mg Warfarin

17237 -0.0131816 0.0131320

-0.1156282

0.0329962

Major Bleeding:
Dabigatran 150mg Warfarin

17226 -0.0041146 0.0238650

-0.0893168

0.6339190

Figure 5
Logistic Pred Prob Difference between Dabigatran 110 mg and Warfarin: Density plot
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Major Bleeding
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Figure 6
Logistic Pred Prob Difference between Dabigatran 150 mg and Warfarin: Density plot
30
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Major Bleeding

Density
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0
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0.00
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To determine the range of patients for whom dabigatran 110mg or dabigatran 150mg
would be superior to warfarin, regarding the risk of stroke or systemic embolism and
major bleeding, we plotted the all patients’ risk on a chart with a two axes chart, one for
each risk (Figures 7 and 8). The X-axis is defined as risk of stroke or systemic embolism
with dabigatran minus risk of stroke or systemic embolism with warfarin, and therefore,
all patients who fall below the zero line, have a lower risk of stroke or systemic embolism
with dabigatran, and those who fall above the zero line have a lower risk of stroke or
systemic embolism with warfarin. The Y-axis is defined as risk of major bleeding with
dabigatran minus risk of stroke or systemic embolism with warfarin, and therefore all
patients who fall to the left of the zero line, have a lower risk of major bleeding with
dabigatran, and those who fall to the right of the zero line, have higher risk of major
bleeding with dabigatran. In summary, those patients who fall in the lower left quadrant
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of the chart would benefit from dabigatran relative to warfarin, as their risk of stroke or
systemic embolism and major bleeding are both lower with dabigatran. Those patients
who fall in the upper right quadrant of the chart would benefit from warfarin relative to
dabigatran, as their risk of stroke or systemic embolism and major bleeding are both
lower with warfarin. However, in the upper left and lower right quadrants, there are
decisional conflicts. The patients in the upper left-hand corner have a lower risk of stroke
with warfarin, but a lower risk of bleeding with dabigatran. The patients in the lower
right-hand corner have a lower risk of stroke with dabigatran, but a lower risk of bleeding
with warfarin. For those a lower these patients in the upper-left, and lower-right hand
corners of the chart, treatment decisions could be made via a well-informed shareddecision-making process, taking into account patients’ concerns, values and differences
in risk-tolerance between stroke or systemic embolism or major bleeding.

Figures 7 and 8 show that for dabigatran 110mg and 150mg versus Warfarin, there are
patients whose stroke or systemic embolism and major bleeding risk combinations fall in
all four classifications. The most notable difference between the two figures is that
dabigatran 150mg figure has many more patients with a lower risk of bleeding with
warfarin, thus explaining why this figure has so many patients who fall in the upper right
quadrant where patients have both a lower stroke or systemic embolism and major
bleeding risk with warfarin.
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Figure 7

Figure 8
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Discussion

In this analysis, we used data from the RE-LY trial to develop two multivariate risk
models to predict patients’ risk of stroke or systemic embolism, and risk of major
bleeding, with treatment with warfarin, dabigatran 110mg and dabigatran 150mg. We
applied these risk models to each patient in the RE-LY trial, found significant
heterogeneity among patients in the benefits and risks of using the three different
medications. For example, some patients derive a much greater benefit than others in
stroke or systemic embolism risk reduction from using dabigatran 110mg versus
warfarin. And other patients derive a much greater risk than others in major hemorrhage
when using dabigatran 150mg compared to warfarin. The range of this heterogeneity of
treatment effect is demonstrated by Table 8 and figures 6-7, which show the distribution
of the differences in absolute risk reduction for each patient when using dabigatran
150mg and dabigatran 110mg versus warfarin. The mean difference (dabigatran minus
warfarin) in the risk of stroke was -0.78% ± 0.95% for dabigatran 110mg and -1.32% ±
1.31% for dabigatran 150mg. The mean difference in the risk of major bleeding was 1.12% ± 1.44% for dabigatran 110mg and -0.41% ± 2.39% for dabigatran 150mg. These
findings confirm our hypothesis that there is a heterogeneity of treatment effect with
regard to dabigatran and warfarin.

The heterogeneity of treatment effect was explained by Figures 2-A and 2-B, which show
the contributions of individual characteristics to the risk of stroke or major bleeding.
Certain variables such as a history of diabetes or heart failure increased the risk of stroke
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or systemic embolism or major bleeding, respectively. Whereas other variables, such as
male gender or region decreased the risk of stroke or systemic embolism or major
bleeding, respectively. These opposing risk factors, with their different weight, can
complicate clinical decision making, and highlight the need for multivariate prediction
models to accurately and objectively weigh individual risks and benefits.

These findings build on recent studies to demonstrate the importance of analyzing clinical
trials for heterogeneity of treatment effect using multivariate risk models. Salisbury et
demonstrate the heterogeneity of treatment effect between clopidogrel and prasugrel in
the TRITON-TIMI 38 trial, and by Kernan et al to demonstrate the heterogeneity of
treatment of pioglitazone post stroke or TIA in the IRIS trial (11,12). Our application of
multivariate risk models to the RE-LY trial similarly found heterogeneity of treatment
effect, that was previously unknown, adding to further evidence regarding the potential
benefit of multivariate predictive risk models to clinical care.

To assess the potential impact of these findings, it is important to return to the current
state of clinical practice and decision making with regard to dabigatran and warfarin. In
the U.S. clinicians and patients choose between doses of dabigatran 150mg and 75mg and
warfarin based on the findings of clinical trials such as RE-LY, and their respective
subgroup analyses. However, while the findings of these trials report means, medians,
standard deviations and the results that are best for the population as whole, they don’t
necessarily reflect the results for patients at the extremes of the treatment effect. For
example, the RE-LY trial found that for the population as a whole, there were similar
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risks of major bleeding with dabigatran 150mg versus warfarin warfarin (15). Our
analysis does not dispute this finding, but rather notes that for certain patients there is a
significantly increased risk of bleeding with dabigatran 150mg compared to warfarin.

Trials such as RE-LY do publish subgroup analyses to account for this heterogeneity of
treatment effect. However, these subgroup analyses have numerous statistical limitations,
can pose opposing risk contributions from the application of different subgroups, and are
not easy for a clinician to practically apply to individual patients in the clinical setting.
Furthermore, while these subgroup analyses certainly narrow the population to the
individual, they still generalize results to a population that shares only one characteristics.
This is akin to Netflix recommending a movie to a 70-year-old woman, because that
movie has been popular among people over the age of 65. Much like Netflix is able to
make a movie prediction to this woman based on her age, gender, the time it takes her to
finish a TV show, and the actresses in previous shows she has finished, modern medicine
has the potential to make individualized medication recommendations based on multiple
individual characteristics.

Most importantly, our findings that there are both patients for whom dabigatran or
warfarin would reduce their risk of stroke and bleeding, demonstrates the potential for
more individualized decisions to improve patient health. These data are displayed
graphically in figures 7 and 8 showing each patients risk along two axes, for risk of
stroke and risk of major bleeding. Those patients who are in the lower left, and upper
right quadrants showed both a greater absolute risk reduction in both stroke or systemic
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embolism and major hemorrhage with dabigatran and warfarin, respectively. The
challenge in the clinical setting, is to identify which quadrant a given patient would fall
in, such that their risk of stroke or major bleeding could be minimized.

The basis of these findings in a multivariate predictive risk model, highlights the potential
for this model to be used in clinical practice to predict patients risks of stroke or bleeding
with dabigatran versus warfarin. Before this risk model is used clinically, it will need to
be tested in further populations. However, if validated, it’s use in clinical practice would
be beneficial, and feasible. Multivariate predictive risk models are already in widespread
use, with clinicians and patients using multivariate risk scores such as CHADSVASC2
and HASBLED to predict their individual benefits and risk with using anticoagulation.
This multivariate predictive risk model could be used in a similar way to help clinicians
and patients make a fully informed, individualized decision about a medication at the
point of care.

While such a tool would identify those patients who would clearly benefit from warfarin
or dabigatran with regard to both stroke and bleeding risk, there will also be patients who
have the lowest stroke risk with one medication, and the lowest bleeding risk with the
other medication. These patients are represented by the upper left and lower right
quadrants in Figures 7 and 8. These treatment decisions pose a challenge, that will require
careful evaluation of the degree of risks and benefits with different given treatment, and a
shared decision-making process to identify the treatment that would best align with
patient preferences and values.

53

To facilitate the decision-making around treatments that carry both a benefit and a risk
with regard to other available treatments, Salisbury et al, proposed the calculation of a
“net clinical benefit score” (11). The net clinical benefit is defined as the benefit to risk
ratio. As applied to our findings, net clinical benefit would be defined as the ratio of the
reduction of risk in stroke or systemic embolism (the benefit), to the increase in risk of
bleeding. For each patient, the benefit of a given treatment, or reduction in risk of stroke
or systemic embolism, would be calculated as the absolute difference of the predicted risk
of stroke or systemic embolism for warfarin minus the predicted risk with dabigatran.
The risk, or increased risk of major hemorrhage, would be calculated as the absolute
difference of the predicted risk of major hemorrhage with warfarin minus the predicted
risk with dabigatran. For each patient a benefit to risk ratio >1, or an absolute benefit with
dabigatran that is greater than the absolute risk with dabigatran, would signify a net
benefit with dabigatran relative to warfarin. A ratio of <1, or an absolute benefit with
dabigatran less than the absolute risk increase with dabigatran, indicates a net benefit
with warfarin relative to dabigatran.

In clinical practice, patients and clinicians may have their own individual perspectives on
the amount of benefit required to outweigh a given risk. For example, some patients and
clinicians might feel that preventing stroke or systemic embolism is twice as important as
avoiding major hemorrhage, while others might feel that preventing stroke or systemic
embolism is half as important as avoiding major hemorrhage. In the first group who put
greater emphasis on reducing stroke, a benefit to risk ratio of >0.5 would be required to
signify a net clinical benefit with dabigatran relative to warfarin. For the second group
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who put greater emphasis on avoiding hemorrhage, a benefit to risk ratio of >2 would be
required to signify a net clinical benefit with dabigatran relative to warfarin (11).

The presentation of such a net clinical benefit score could help patients and clinicians
simplify challenging decisions. Such a tool could be part of a larger strategy to
communicate risk in an intuitive fashion, and to facilitate the use of multivariate
predictive models in clinical decision making.
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Effective presentation of risk models to facilitate shared decision making

The promise of individualized patient data, is its potential to guide clinical decisionmaking. Thus, as we develop methods to provide more individualized data, we must also
develop tools to present the data in a way that can most effectively aid decision-makers.

These tools can be used as part of the shared-decision making model, which is designed
to enhance patient clinician communication, and ensure treatment decisions that are
backed by all available evidence, and align with patient values (20). Shared decision
making is recommended by the American Heart Association for anticoagulant treatment
decisions in AF, to ensure that treatment decisions are aligned with patient’s values (14).

The shared decision-making model consists of a clinician and patient forming a
partnership, through which the clinician explains the risks and benefits of different
treatment options, patients explain their experiences, values and thoughts about different
treatments, and together the patients and clinicians discuss their thoughts about the
treatment options, and agree on a course forward (20-23). There is of course a range of
the degree to which different patients wish to be involved in the decision-making process,
and it is important for clinicians, at the outset, to ask patients what they would prefer.
This might range from the patient seeking information and making the decision, to the
patient asking the doctor’s opinion and then making the decision, to asking the doctor to
make a decision by themselves (24). However, it is important that clinicians do not
assume patient deference to their provider, as it has been shown that patients randomized
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to participate in shared decision making versus usual care, report greater satisfaction
(20,25).

Visual decision aids can greatly enhance the shared decision-making process by helping
the clinician convey treatment risk and benefit information in a clear and easy to
understand manner (20). Effective decision-aids incorporate a number of principles that
have been learned from behavioral decision-making science and studies of past decision
aids.

First, decision-aids should avoid use of number needed to treat statistics and relative risk
statistics. Number needed to treat is a difficult concept for many patients to understand,
and relative risk can lead both patients and clinicians to perceive an exaggerated risk or
treatment effect. As an example of this phenomenon with relative risk, a patient who is
told that a given treatment will reduce their risk of stroke by 50%, is will likely be more
inclined to use the drug than if they were told that it reduced their risk of stroke from 2%
to 1% (26). Furthermore, as previously discussed, a relative risk reduction of 50% may
have significantly different implications for a patient who sees their risk decrease from
20% to 10% versus a patient who sees their risk decrease from 2% to 1%. Therefore, in
order to avoid an exaggeration of treatment effect, and to ensure that risks are truly
individualized, decision-aids should present risks as absolute risks (24,27,28).

In addition to presenting risks as absolute risks, it is also important for decision aids to
convey the incremental change in risk, from the patient’s baseline risk. If a clinician tells
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a patient that they have a 5% risk of major bleeding over the next 10 years with a given
anticoagulant, they may incorrectly assume that all of their bleeding risk is due to the
anticoagulant, and that their risk without treatment would be 0%. Therefore, if the patient
has a 4% baseline risk of bleeding without treatment over the course of 10 years, it is
important to convey that information, and to explain that taking the anticoagulant will
add 1% to their absolute risk of bleeding over 10 years (27,28).

Similarly, it may be helpful to provide patients with contextual absolute risk information
about their other health risks, as a basis of comparison for the risks associated with
treatments. For example, if a patient is weighing whether to take a drug that is associated
with a 1% absolute risk of bleeding over 10 years, it may be helpful for them to
understand that their absolute risk of carotid artery disease over that same period is 40%
(27).

When comparing the absolute risks associated with multiple treatments, it is important
for decision aids to convey those risks in consistent formats. That is, if one risk is
presented as a percent, the other risk should be presented as a percent, not as a frequency
ratio. People, especially with lower numeracy, which tends to decrease with age, may
have difficulty comparing a 7% risk to a 5/100 risk, and it has been found that people
tend to be biased, in perceiving frequencies as being greater than percents (27,29,30).
Therefore, a 7% risk should be compared to a 5% risk, or a 7/100 risk should be
compared to 5/100 risk. Furthermore, if the risks are presented as frequency ratios, it is
important that the ratios have identical denominators. A 2/50 risk of bleeding with drug A
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should not be compared to a 6/75 risk with drug B. Rather, this should be presented as a
4/100 risk with drug A, compared to an 8/100 risk with drug B. Additionally, it is best to
avoid presenting frequencies in a “1 in x” format, as this has been found to be difficult for
patients to understand (27,31). And, when possible, it is best to use smaller denominators.
A 1/10 risk is found to be much better intuitively understood than a 1/100 risk (27,32).

There is significant debate on the role of narrative language on decision aids. The
generally agreed upon notion is that “words matter.” The challenge then is to determine
when they serve to add helpful additional information, versus when they introduce or
exacerbate anecdote bias. For example, the inclusion of patient testimonials on decision
aids has been found to make patients more concerned about the severity of bad outcomes
(27,33). For a patient who views a cerebral hemorrhage as akin to a bruise on their
forehead, the inclusion of such a testimonial would be warranted. However, for the
patient whose friend recently died of a cerebral hemorrhage, the sharing a testimonial of
cerebral hemorrhage might further bias them to overestimate the likelihood of a
hemorrhage in their decision-making process. In fact, one of the greatest benefits of
visual decision-aids, is their ability to reduce anecdote bias, and allow patients and
clinicians to consider data is as objective a way as possible, so they can make decisions in
line with their values (27,34).

Language can also be added to decision-aids in order to “label” results. For example,
rather than only telling patients that the risk of hemorrhage is 1% with one drug and 5%
with another drug, a decision aid could label the 1% risk as “low,” and the 5% risk as
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“high.” Patients given decision aids with labels were found to be more likely to
incorporate risk information in their decision-making (27,35).

Decision-aids can introduce “framing effects” through which different presentations of
identical information, can lead to different patient decisions. Numerous studies have
demonstrated that patients are more likely to tolerate risky medications or procedures if
the risks of procedures were framed in a positive as opposed to negative frame (27,36).
For example, Levin et al, showed that people were hypothetically more willing to
undergo a procedure with a 50% success rate than a procedure with a 50% failure rate
(37). This line of reasoning suggests that patients would be more inclined to take an
anticoagulant if they are told “95% of patients with AF who take Warfarin don’t have a
stroke within 10 years,” compared to being told that “5% of patients with AF who take
warfarin have a stroke within 10 years.”b The presence of framing effects should not be
used to influence patient decisions, but should be considered as potential sources of
biases in patient decisions.

The “recency effect” is another bias that can be introduced by decision aids. In this bias,
patients are more likely to place greater emphasis on the piece of information they heard
last (28,38). For example, if a patient is first told about an anticoagulant’s association
with hemorrhage, and are then told about its’ effect on stroke prevention, they may place
disproportionate weight on the drug’s impact on stroke prevention. And if they are first
told about stroke prevention, and then told about hemorrhage, they may place greater

b

This a hypothetical deduction of previous study findings, and has not itself been studied.
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emphasis on hemorrhage.c To reduce this bias, decision-aids can summarize all presented
information, prior to the patient decision, such that the value patients place on a given
treatment characteristic, is consistent with their own personal values and not with the
order in which it was presented (28).
The visual presentation of decision-aids may also influence comprehension. First, while
the use of numbers to present statistical information, may be the best way to convey
precise, or verbatim, information, there are many benefits to conveying information
through pictographs. Pictographs present statistics by using different colored icons
(usually ovals, smiley faces, or bathroom symbols) to represent the affected proportion of
an at-risk population. For example, to convey that 3/100 people who take an
anticoagulant get a cerebral hemorrhage within 10 years, a pictograph might display 100
bathroom figures, and color three of them red, signifying the likelihood of cerebral
hemorrhage. Though it has been proposed that these three red figures be spread out
among the pictograph, to emphasize the randomness of an event occurring, it has been
found that comprehension increases when they are grouped together (27,39). Pictographs
can be intuitively easy to understand, and have been shown to be better than bar graphs in
conveying “gist” knowledge. Furthermore, while the use of numbers is the most effective
way to convey precise, or verbatim, information, pictographs are superior to pie graphs in
conveying verbatim knowledge (28,40).

The major benefit of pictographs however, is their ability to address “denominator
neglect” (41). Through this bias, people tend to overweigh numerators, and under weigh

c

This a hypothetical deduction of previous study findings, and has not itself been studied.
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denominators. For example, many people are likely to believe that a 15/100 risk is greater
than a 2/10 risk (41). Icon arrays draw people’s eyes to the denominator, to help them
understand the context of the numerator and to get a more accurate understanding of their
risk. The presentation of too much information can distract patients from key points such
as the denominator, and it is therefore essential that pictographs include only the most
important information (28,42).

In addition to “neglecting” the denominator, it is also common for people to
misunderstand the meaning of the denominator. For example, a patient who is told they
have a 3/100 risk of hemorrhage, may assume that every 3/100 times they take an
anticoagulant, they can expect to get a hemorrhage, and that nearly everybody eventually
gets a hemorrhage (27,43). Icon arrays provide a shared mental model through which
clinicians can work with patients to ensure that they accurately understand the meaning
of the denominator and how it relates to their individual risk.

Finally, icon arrays have the potential to address neglect of a time course. Risk is defined
as events/at risk population over a given time period. However, this time period is often
neglected. For example, patients who are told they have a 10-year, 3/100 risk of
hemorrhage may assume that every single year, for 10 years, 3 people out of 100 will
suffer a hemorrhage, for a total of 30 people out of 100 at the end of 10 years. Icon arrays
should clearly display the time course of a risk, and again, help clinicians and patients
work together under a shared mental model (27).
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The use of shared decision making with decision aids increases patients’ knowledge of
pre-treatment risk and treatment options, increases patient engagement and decreases
decisional conflict (20,44,45). Furthermore, decision-aids that are tailored to patient’s
individual profile have been shown to have a particularly strong positive impact on
patient comprehension (27,46). There have also been number of studies of shared
decision making and decision aids regarding anticoagulation in AF. While many of these
studies were done without individual risk models and prior to non-vitamin K oral
anticoagulants, similar to other studies of shared decision-making, they found that
patients who underwent shared decision making, had greater understanding of treatment
options, and decreased decisional conflict (20,47).

The multivariate predictive risk models for stroke or systemic embolism and major
bleeding developed in this analysis, if validated, could be incorporated into decision-aids
in order to help clinicians and patients with AF and an increased risk of stroke, work
together to make decisions about anticoagulation with dabigatran versus Warfarin. The
following icon arrays were generated using http://www.iconarray.com, a tool developed
by the Risk Science Center at the University of Michigan, which incorporates many of
the lessons from the decision-aid literature, to create effective decision-aids (48).

These are examples of decision-aids that could be presented to two different patients. The
first patient is Frank, a 62-year-old, 85 kg man with diabetes, a creatinine clearance of 85
ml/min, a history of TIA, and permanent AF, who is taking Aspirin, and has no history of
heart failure. The second patient is Maria, an 87-year-old, 58 kg woman who also has
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diabetes, a creatinine clearance of 85ml/min, has persistent AF and is taking aspirin, and
has no history of stroke, systemic embolism, TIA or heart failure.

For each patient, the decision-aids show their risk of stroke with dabigatran 150mg and
warfarin, side-by side, and below that, their risk of major bleeding with dabigatran
150mg and warfarin, side-by side.

As seen in the decision-aids, both patients face decisional challenges. Frank’s risk of
stroke is higher with warfarin, at 3.84% than it is with dabigatran, at 0.92%. However, his
risk of major bleeding is lower with warfarin, at 8.43% than it is with dabigatran, at
13.1%. Maria’s risk of stroke is slightly higher, with warfarin, at 2.4% than it is with
dabigatran, at 1.49%. However, her risk of major bleeding is much lower with warfarin,
at 8.51% than it is with dabigatran at 22.12%.
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Frank and Maria, could both look at these personalized decision-aids with their physician,
as part of a regular office visit, in order to understand the different risks and benefits
associated with an anticoagulant, and alongside other considerations such as lifestyle
implications, could make a fully informed choice that aligns with their respective values.
Frank might have a very active lifestyle, and given his relatively young age of 62 and his
history of TIA, might be very concerned about a stroke causing functional limitation, and
might be willing to accept the risk of major bleeding requiring a transfusion. In this case,
Frank would likely choose dabigatran given that it decreases his risk of stroke by close to
3% relative to warfarin, even though it is associated with an over 4% increased risk of
bleeding. Maria on the other hand, at age 87, might have numerous functional limitations,
and might be more concerned about being hospitalized for major bleeding issues than she
is about new functional limitations from a stroke. In this case, Maria might be
unimpressed by the approximately 1% decreased risk of stroke with dabigatran relative to
warfarin, but might be very concerned by the nearly 14% increased risk of major
bleeding with dabigatran and would therefore be likely to choose warfarin. In such cases
where patients place different weight on the risks of stroke and major bleeding, a net
clinical benefit score as discussed earlier, could also play a role in calculating for the
patient, which treatment choice would best align with their values and preferences.

Such an aid could also theoretically be interactive, and further engage patients by
providing them an opportunity change the variables in the model. For example, Frank
could see how his risk of stroke will change as he gets older, and Maria could see how
her risk of major bleeding would change if her creatinine clearance were to decrease.
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It is important to note that this graphic has not been tested, and only serves to highlight
how a pictograph decision-aid could potentially convey information from the predictive
risk model to patients as part of their usual care. Decision-aids should be studied for
effectiveness with regard to decisional factors such as patient comprehension, decisional
conflict and decision comfort.

While risk models can be created, and decision-aids can be built, they will only be
valuable if patients and clinicians use them during clinical practice. Given the potential
for numerous risk models to be developed and updated over the coming years and
decades, it is important to build an infrastructure that provides patients and clinicians
with the latest and most relevant risk models in an easily accessible manner. One
potential example of such an infrastructure, would be a risk calculator that is
automatically built in to the electronic medical record, and that quickly displays decision
aids onto a tablet that is readily available in the exam room, or to a patient’s smartphone.
In addition to improving awareness and accessibility of newly developed risk models,
one of the biggest challenges to the use of shared decision making and decision aids, is
their potential impact on clinical workflow. Studies have found that shared decision
making can add approximately 3 minutes to a clinical encounter (20,49). While
incorporating automated systems into electronic medical records may add some
efficiency, it is also important that shared decision making is valued by payers and health
systems, such that time for shared decision making is allocated as a part of standard
practice.
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Conclusion

This study demonstrates that there is heterogeneity of treatment effect between
dabigatran 110mg and dabigatran 150mg versus Warfarin for the RE-LY population.
These findings were demonstrated through a multivariate predictive risk model that has
the potential to be used in clinical practice to predict treatment effect. However, prior to
use in clinical practice, the effectiveness predictive risk model will need to be evaluated
against other populations. If validated, this model could enhance the shared decisionmaking process by providing patients with easy-to-understand individualized information
about their predicted risks and benefits with a given treatment.

However, there are a number of limitations to our study.

First, the multivariate predictive risk model has not been tested against independent
populations outside of the RE-LY trial. To account for this limitation, we conducted a
bootstrapping procedure, which tested the model on small samples of the RE-LY
population against the rest of the population. However, internally validated models, due
to the fact that they developed and tested with the same population, may be subject to
limitations in generalizability. Thus, prior to use in clinical practice, it is important for
this model to be tested external, independent samples.

Second, the generalizability of our model is limited by the inclusion and exclusion
criteria of the RE-LY trial. Patients in the RE-LY trial were limited to those with AF and
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an increased risk of stroke. Patients who were pregnant, had active liver disease, a
creatinine clearance below 30 ml/min, or had a severe heart valve disorder were excluded
from the study. However, the RE-LY trial population was designed to include those
patients most likely to face a treatment decision of dabigatran versus warfarin, and
despite the limitations of the inclusion and exclusion criteria, the model designed in this
study should still have widespread clinical applicability.

Third, the c-statistic, or area under the curve of our model, was only is 0.675 for the
stroke model and 0.694 for the major bleeding model. These c-statistics represent some
limitation in the degree of discrimination of the model and its ability to predict events
versus non-events. However, as noted by Salisbury et al, predictive models with modest
c-statistics are superior to the generalization of findings across a broad population, and
models with c-statistics greater than 0.60 have been shown to be effective (4,11).

Last, the models in this study only predict individualized risk for stroke and systemic
embolism, and major bleeding. Patients may also be interested in other individualized
information, such as their risk of myocardial infarction with each treatment option, or
lifestyle implications of each medication. However, stroke and systemic embolism and
major bleeding were selected for this study, because they are generally seen as the
biggest risk and benefit concerns of anticoagulant choice in patients with AF and an
increased risk of stroke. And these individualized risks do not need to be used in
isolation, but rather as information alongside other considerations such as lifestyle
implications as part of a comprehensive treatment decision.

70

Despite these limitations, this analysis shows that heterogeneity of treatment effect exists
in the RE-LY trial, building on evidence that it exists in other trials. The multivariate
model developed in this study demonstrates the potential of this model, if further
validated, to be used in clinical practice to help patients understand their individualized
risk and benefit with regard to taking warfarin or different doses of dabigatran.

The increasing amount of data available in medicine poses a potential for unique
statistical profiles to be developed for patients, such that they can make individualized
decisions to maximize their benefits, minimize their risks and improve their health. The
use of multivariate predictive risk models, such as that published in this analysis, have the
potential to move clinical practice closer to this goal of precision medicine.

But for multivariate predictive risk models to be used effectively in clinical practice, their
findings must be clearly communicated and easily understood. In addition to recognizing
the potential of unique statistical profiles to help batters hit a baseball, Ted Williams
communicated this potentially complicated concept through a simple illustration of the
strike zone that could be intuitively understood by boys and girls across cultures and
generations. Using the science behind visual decision aids and effective presentation of
statistics, we too can work to ensure that it is just as intuitive for a patient and clinician to
use a risk model to choose between dabigatran and warfarin, as it was for a young
baseball hitter to use Ted Williams’ strike zone graphic to choose “a good ball to hit” (1).
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